Učitavanje...
Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab
OBJECTIVE: To analyse malignancy rates in patients with rheumatoid arthritis (RA) treated with tocilizumab. METHODS: Patients who received tocilizumab or placebo+methotrexate/disease-modifying antirheumatic drugs in the double-blind phases of 5-phase three trials or who received at least 1 dose of t...
Spremljeno u:
| Izdano u: | RMD Open |
|---|---|
| Glavni autori: | , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BMJ Publishing Group
2016
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4874056/ https://ncbi.nlm.nih.gov/pubmed/27252893 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2015-000213 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|